Latest updates for Biib
Fresh curated links around BIIB are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- BioXcel files for Chapter 11, will sell assets to Teva
- TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
- AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
fiercebiotech.com
/1 month ago
AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into p...
seekingalpha.com
/1 month ago
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
cafepharma.com
/1 week ago
BioXcel
BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...
pharmexec.com
/2 weeks ago
<![CDATA[FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older]]>
seekingalpha.com
/1 month ago
ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
qchron.com
/2 weeks ago
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
pharmexec.com
/2 weeks ago
<![CDATA[Pharmaceutical Executive Daily: FDA Approves Imaavy for wAIHA]]>
pharmexec.com
/1 month ago
<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>
cafepharma.com
/1 month ago
INVIVYD
INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...
seekingalpha.com
/4 days ago
Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum
pharmexec.com
/1 week ago
<
biopharmadive.com
/1 month ago
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
pharmexec.com
/1 month ago
<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>
seekingalpha.com
/1 month ago
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline
pharmexec.com
/1 month ago
<![CDATA[FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults ]]>
fool.com
/1 month ago
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.
fiercebiotech.com
/1 week ago
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Biib
seekingalpha.com
Recent coverage from public sources
Public source
cafepharma.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source
fiercebiotech.com
Recent coverage from public sources
Public source